Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
CHARM Therapeutics Receives Investment for Deep Learning-Enabled Drug Discovery Research from NVIDIA
Details : The financing will be used to identify potential new compounds using company's proprietary DragonFold platform enabling the company to bring potential new therapies through protein-ligand co-folding.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 15, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Discovery
Sponsor : Bristol Myers Squibb
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration will leverage CHARM’s DragonFold deep learning platform that identifies novel molecules through protein-ligand co-folding, to discover novel compounds against targets of interest to Bristol Myers Squibb.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
March 20, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Discovery
Sponsor : Bristol Myers Squibb
Deal Size : Undisclosed
Deal Type : Collaboration
Reset All
